CA 27.29

Order Name: **CA27.29**
Test Number: 2024375
Revision Date: 12/12/2022

TEST NAME	METHODOLOGY	LOINC CODE
CA 27.29	Immunochemiluminometric (ICMA)	17842-6

SPECIMEN REQUIREMENTS

Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	**1mL (0.3)**	**Serum**	**Clot Activator SST**	**Refrigerated**

Instructions

Notes: 0.3 mL (Note: This volume Does NOT allow for repeat testing.)
Specimen Type: Red-top tube or gel-barrier tube
Specimen Storage: Refrigerated
Specimen Collection: If a red-top tube is used, transfer the separated serum to a plastic transport tube.
Special Instructions: It is recommended that one assay method be used consistently to monitor a patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only.
Specimen Stability: Ambient: Not Available, Refrigerated : 5 days, Frozen: Greater than 1 month

GENERAL INFORMATION

Expected TAT	1-2 days
Clinical Use	The CA 27.29 assay is intended for use in monitoring: 1) disease progression and/or response to therapy in patients with metastatic disease, and 2) disease recurrence in patients treated previously for stages II or III breast carcinoma who are clinically free of the disease. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods for early detection of cancer recurrence. Limitations: Patients with confirmed breast carcinoma frequently have CA 27.29 assay values in the same range as healthy individuals. Elevations may also be observed in patients with non-malignant disease. Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy
Performing Labcorp Test Code	140293
Notes	Labcorp Test Code: 140293
CPT Code(s)	86300
Lab Section	Reference Lab